Prevalence of Hepatitis B Virus Infection Among Iranian High Risk Groups: a Systematic Review and Meta-analysis

Overview

Journal Gastroenterol Hepatol Bed Bench

Specialty Gastroenterology

Date 2018 Jun 19

PMID 29910849

Citations 4

Authors

Amir Almasi-Hashiani

Erfan Ayubi

Kamyar Mansori

Mostafa Salehi-Vaziri

Yousef Moradi

Behzad Gholamaliei

Salman Khazaei

Affiliations

Soon will be listed here.

Abstract

Aim: Present study aimed to systematically review and quantitatively synthesize published data about the prevalence of Hepatitis B Virus (HBV) infection among high risk groups in Iran.

Background: Determining true burden of Hepatitis B Virus (HBV) infection among high-risk groups relies on knowledge of occurrence measures such as prevalence rate. There is no conclusive and comprehensive data regarding to prevalence of HBV infection among high risk groups in Iran.

Methods: Relevant studies were searched in PubMed, Scopus, Web of Knowledge and local databases. In addition, reference lists of relevant studies were searched manually. Two independent authors reviewed the eligibility of retrieved studies and extracted the required data. Studies reporting HBV infection among high risk groups were included in the meta-analysis using random effects models. Meta regression and sub-group analysis were considered as additional analyses.

Results: The initial search yielded 566 citations. After the primary screen, 37 studies were selected for review. Meta-analysis results showed that pooled prevalence of HBV infection among high risk groups in Iran was 4.8% (95% confidence interval: 3.6%-6.1%), with the highest prevalence among in prisoners (5%; 3%-6%), and in central regions of Iran (7%; 4%-11%). Year of study may affect the observed heterogeneity in the estimated prevalence of HBV infection among injection drug users (IDUs) and prisoners.

Conclusion: Our results indicate that prevalence of HBV infection among high risk groups was seemingly high in Iran. Health policy decision makers should be aware of prevalence of HBV infection among different high risk groups and in different regions of Iran.

Citing Articles

Prevalence of HBV and HCV Infections in Iranian Blood Donors; An Updated Systematic Review and Meta-Analysis.

Kasraian L, Imanieh M, Tabrizi R, Shahriarirad R, Erfani A, Hosseini S Middle East J Dig Dis. 2023; 13(3):237-252.

PMID: 36606217 PMC: 9489455. DOI: 10.34172/mejdd.2021.231.

Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts.

Brown R, Goulder P, Matthews P Wellcome Open Res. 2022; 7:32.

PMID: 36212217 PMC: 9520633. DOI: 10.12688/wellcomeopenres.17601.2.

Hepatitis B virus infection among people who use drugs in Iran: a systematic review, meta-analysis, and trend analysis.

Rostam-Abadi Y, Rafiemanesh H, Gholami J, Shadloo B, Amin-Esmaeili M, Rahimi-Movaghar A Harm Reduct J. 2020; 17(1):81.

PMID: 33087141 PMC: 7579800. DOI: 10.1186/s12954-020-00424-w.

How much does vaccination reduce the rate of HBV infection in Iranian population? a Bayesian adjustment analysis.

Shojaee S, Zayeri F, Nasserinejad M, Ghasemzadeh A, Beheshti Shirazi S, Khodadoostan M Gastroenterol Hepatol Bed Bench. 2020; 12(Suppl1):S136-S144.

PMID: 32099614 PMC: 7011057.

References

Schweitzer A, Horn J, Mikolajczyk R, Krause G, Ott J . Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386(10003):1546-55. DOI: 10.1016/S0140-6736(15)61412-X. View

Nelson P, Mathers B, Cowie B, Hagan H, Des Jarlais D, Horyniak D . Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011; 378(9791):571-83. PMC: 3285467. DOI: 10.1016/S0140-6736(11)61097-0. View

Nokhodian Z, Yazdani M, Yaran M, Shoaei P, Mirian M, Ataei B . Prevalence and Risk Factors of HIV, Syphilis, Hepatitis B and C Among Female Prisoners in Isfahan, Iran. Hepat Mon. 2012; 12(7):442-7. PMC: 3437455. DOI: 10.5812/hepatmon.6144. View

SeyedAlinaghi S, Kheirandish P, Karami N, Salem S, Shirzad H, Reza Jahani M . High prevalence of chronic hepatitis B infection among injection drug users in Iran: the need to increase vaccination of adults at risk. Acta Med Iran. 2010; 48(1):58-60. View

Sharif M, Sherif A, Sayyah M . Frequency of HBV, HCV and HIV infections among hospitalized injecting drug users in Kashan. Indian J Sex Transm Dis AIDS. 2011; 30(1):28-30. PMC: 3168036. DOI: 10.4103/0253-7184.55477. View

Talaie H, Shadnia S, Okazi A, Pajouhmand A, Hasanian H, Arianpoor H . The prevalence of hepatitis B, hepatitis C and HIV infections in non-IV drug opioid poisoned patients in Tehran-Iran. Pak J Biol Sci. 2008; 10(2):220-4. DOI: 10.3923/pjbs.2007.220.224. View

Liang T . Hepatitis B: the virus and disease. Hepatology. 2009; 49(5 Suppl):S13-21. PMC: 2809016. DOI: 10.1002/hep.22881. View

Shepard C, Simard E, Finelli L, Fiore A, Bell B . Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 2006; 28:112-25. DOI: 10.1093/epirev/mxj009. View

Moayedi-Nia S, Bayat Jozani Z, Esmaeeli Djavid G, Entekhabi F, Bayanolhagh S, Saatian M . HIV, HCV, HBV, HSV, and syphilis prevalence among female sex workers in Tehran, Iran, by using respondent-driven sampling. AIDS Care. 2015; 28(4):487-90. DOI: 10.1080/09540121.2015.1109582. View

10.

Sofian M, Aghakhani A, Banifazl M, Azadmanesh K, Farazi A, McFarland W . Viral hepatitis and HIV infection among injection drug users in a central Iranian City. J Addict Med. 2012; 6(4):292-6. DOI: 10.1097/ADM.0b013e3182659928. View

11.

Jahani M, Alavian S, Shirzad H, Kabir A, Hajarizadeh B . Distribution and risk factors of hepatitis B, hepatitis C, and HIV infection in a female population with "illegal social behaviour". Sex Transm Infect. 2005; 81(2):185. PMC: 1764649. DOI: 10.1136/sti.2004.011114. View

12.

Mizusawa M, Perlman D, Lucido D, Salomon N . Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons. Int J STD AIDS. 2013; 25(3):201-6. PMC: 4442633. DOI: 10.1177/0956462413495820. View

13.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

14.

Amin-Esmaeili M, Rahimi-Movaghar A, Razaghi E, Baghestani A, Jafari S . Factors Correlated With Hepatitis C and B Virus Infections Among Injecting Drug Users in Tehran, IR Iran. Hepat Mon. 2012; 12(1):23-31. PMC: 3298872. DOI: 10.5812/kowsar.1735143X.806. View

15.

Alter M . Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2005; 44(1 Suppl):S6-9. DOI: 10.1016/j.jhep.2005.11.004. View

16.

Nokhodian Z, Yaran M, Adibi P, Kassaian N, Meshkati M, Ataei B . Seroprevalence of hepatitis B markers among incarcerated intravenous drug users. J Res Med Sci. 2014; 19(Suppl 1):S13-6. PMC: 4078382. View

17.

Zamani S, Radfar R, Nematollahi P, Fadaie R, Meshkati M, Mortazavi S . Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peer-driven sampling in Iran. Int J Drug Policy. 2010; 21(6):493-500. DOI: 10.1016/j.drugpo.2010.04.006. View

18.

Kassaian N, Ataei B, Yaran M, Babak A, Shoaei P . Hepatitis B and C among women with illegal social behavior in Isfahan, Iran: Seroprevalence and associated factors. Hepat Mon. 2011; 11(5):368-71. PMC: 3212782. View

19.

Poorolajal J, Majdzadeh R . Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci. 2011; 14(4):249-58. PMC: 3129112. View

20.

Ziaee M, Sharifzadeh G, Namaee M, Fereidouni M . Prevalence of HIV and Hepatitis B, C, D Infections and Their Associated Risk Factors among Prisoners in Southern Khorasan Province, Iran. Iran J Public Health. 2015; 43(2):229-34. PMC: 4450691. View